Applications of vorinostat in aspect of drugs for treating autoimmune diseases and inflammatory diseases

An autoimmune, vorinostat technology for allergic diseases, blood diseases, sensory diseases, etc.

Inactive Publication Date: 2012-11-28
TIANJIN MEDICAL UNIV
View PDF5 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

However, there is no report on the regulation of vorinostat on EAE mediated by helper T cell TH1 and TH17 subsets of inflammatory response and its therapeutic effect on multiple sclerosis.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Applications of vorinostat in aspect of drugs for treating autoimmune diseases and inflammatory diseases
  • Applications of vorinostat in aspect of drugs for treating autoimmune diseases and inflammatory diseases
  • Applications of vorinostat in aspect of drugs for treating autoimmune diseases and inflammatory diseases

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0023] 1.1 The construction principle of experimental autoimmune encephalomyelitis (EAE) mouse model

[0024] Myelin oligodendrocyte glycoprotein (MOG 35-55 ) MEVGWYRSPFSRVVHLYRNGK was used as an antigen to immunize C57BL / 6 mice to establish MOG 35-55 - EAE (Experimental Autoimmune Encephalomyelitis) mouse model. Commonly used allergens in the laboratory are mostly brain or spinal cord tissue homogenate, myelin basic protein components or their polypeptide fragments, etc. Most of the immunized objects are rodents to build EAE models. Different allergens can produce different symptoms. For the EAE model, different allergens and different immunized objects can be selected according to the type of EAE model to be established. Although the myelin oligodendrocyte glycoprotein used in this experiment has very little content in the myelin protein, accounting for only 0.01%-0.05% of the myelin protein composition, but because MOG exists in the myelin sheath membrane and oligodendroc...

Embodiment 2

[0082] Mix 50g of vorinostat raw material with 280g of starch evenly, make granules with starch slurry (take 220g of starch to make starch slurry with water), sieve, dry, and pack into capsules.

Embodiment 3

[0084] Mix 80g of vorinostat raw material with 340g of starch evenly, use starch slurry (take 210g of starch to make starch slurry with water), make granules, sieve, dry, add 6‰ magnesium stearate, mix well, press into tablets, and wrap film Get the clothes.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention discloses applications of vorinostat in aspect of drugs for treating autoimmune diseases. The experiment result disclosed by the invention shows that due to the vorinostat, the morbidity of the experimental autoimmune encephalomyelitis of mice is reudced, and also the average score, the highest score and the total score of clinical marks are reduced; spinal cord inflammatory cell infiltration and spinal cord demyelination can be alleviated; the weight percent of a cell Th1 related to IFN (Interferon)-gamma secretion and a cell Th17 cell related to IL-17A secretion accounting for positive T cells CD4 in the spleen can be reduced. Therefore the invention relates to the preparation of the drug for inhibiting the experimental autoimmune encephalomyelitis of an animal model, and the drug is expected to treat the diseases related to multiple sclerosis, ophthalmoneuromyelitis, acute disseminated encephalomyelitis and the like.

Description

technical field [0001] The invention belongs to the technical field of medicinal chemistry application and relates to the application of Vorinostat in the preparation of medicine for treating multiple sclerosis and its animal model experimental autoimmune encephalomyelitis. Background technique [0002] Multiple sclerosis (MS) is characterized by demyelinating lesions of the white matter of the central nervous system. Muscle weakness, depression, difficulty with coordination and speech, severe fatigue, cognitive impairment, balance disturbance, body heat and pain, etc., can lead to mobility impairment and disability in severe cases. The cause of multiple sclerosis is unknown, but it is mostly thought to be an autoimmune disease. So far there is no sure and effective cure. [0003] Experimental autoimmune encephalomyelitis (EAE) is caused by isotype, allotype, and heterotype of encephalitic antigens such as myelin lipoprotein (PLP), myelin basic protein (MBP), myelin Sheat...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61P27/02A61P25/00A61P13/12A61P21/00A61P1/16A61P25/28A61K31/167A61P21/04A61P37/02A61P7/00A61P7/06
Inventor 张荣信葛禛禛薛振毅张凯
Owner TIANJIN MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap